Building on AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray Therapeutics’ gene therapy for patients living with
September 06, 2022 08:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Ray Therapeutics, a biotech company whose mission is to restore vision to patients with blinding
– Funding will Advance Development of Ray Therapeutics’ Optogenetics Technology Platform – Company will Advance Ray-001 for the Treatment of Retinitis Pigmentosa SAN DIEGO–(BUSINESS WIRE)–
Posted on March 1, 2022 (March 1, 2022) by Forge Biologics SAN DIEGO, CALIFORNIA AND COLUMBUS, OHIO March 1, 2022 – Ray Therapeutics, a biotechnology company developing optogenetic gene therapies
Top-tier advanced therapies investor 4BIO Capital led the financing round.
The financing will be used to advance its lead optogenetics gene therapy Ray-001 into clinical trials for retinitis pigmentosa.
